{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:35:02Z","timestamp":1791005702860,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The NNRTI doravirine has been recently approved for the first-line treatment of HIV-infected patients, eliciting favourable responses against viruses bearing the K103N, Y181C and G190A mutations. This study used in vitro drug selections to elaborate the breadth of doravirine responses against viruses bearing NNRTI and NRTI resistance-associated mutations (RAMs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>WT clinical isolates (n\u200a=\u200a6) and viruses harbouring common NRTI and NNRTI RAMs (n\u200a=\u200a6) were serially passaged in escalating concentrations of doravirine, doravirine\/islatravir, doravirine\/lamivudine and rilpivirine over 24 weeks. Genotypic analysis ascertained the appearance and accumulation of NNRTI RAMs. Phenotypic drug susceptibility assays assessed resistance conferred by acquired NNRTI RAMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For WT viruses, doravirine pressure led to the appearance of V108I or V106A\/I\/M RAMs after 8 weeks, conferring low-level (\u223c2-fold) resistance. After 24 weeks, the accumulation of three to six secondary RAMs, including F227L, M230L, L234I and\/or Y318, resulted in high-level (&amp;gt;100-fold) resistance to doravirine. Notably, viruses with these doravirine RAMs remained susceptible to rilpivirine and efavirenz. This contrasted with rilpivirine where acquisition of E138K, L100I and\/or K101E resulted in &amp;gt;50-fold cross-resistance to all NNRTIs. Doravirine selection of viruses bearing common NRTI and NNRTI RAMs showed delayed acquisition of RAMs compared with WT virus. Pairing doravirine with islatravir or lamivudine attenuated the development of NNRTI RAMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Doravirine showed favourable resistance profiles against viruses harbouring NRTI and NNRTI RAMs. The high barrier to resistance to doravirine coupled with the long intracellular half-life of islatravir may provide the opportunity for long-acting treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkad184","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T23:22:51Z","timestamp":1685575371000},"page":"1921-1928","source":"Crossref","is-referenced-by-count":19,"title":["Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under\n                    <i>in vitro<\/i>\n                    selective drug pressure"],"prefix":"10.1093","volume":"78","author":[{"given":"Bluma G","family":"Brenner","sequence":"first","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Oliveira","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxandra-Ilinca","family":"Ibanescu","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9897-7589","authenticated-orcid":false,"given":"Jean-Pierre","family":"Routy","sequence":"additional","affiliation":[{"name":"Chronic Viral Illness Service, McGill University Health Centre , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9jean","family":"Thomas","sequence":"additional","affiliation":[{"name":"Clinique m\u00e9dicale l\u2019Actuel , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"2023080202261538200_dkad184-B1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/v10010010","article-title":"Genotypic and phylogenetic insights on prevention of the spread of HIV-1 and drug resistance in \u201creal-world\u201d settings","volume":"10","author":"Brenner","year":"2018","journal-title":"Viruses"},{"key":"2023080202261538200_dkad184-B2","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":"Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis","volume":"380","author":"Gupta","year":"2012","journal-title":"Lancet"},{"key":"2023080202261538200_dkad184-B3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/QAI.0000000000002496","article-title":"Review of doravirine resistance patterns identified in participants during clinical development","volume":"85","author":"Martin","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023080202261538200_dkad184-B4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/jac\/dky464","article-title":"Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients","volume":"74","author":"Soulie","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023080202261538200_dkad184-B5","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202261538200_dkad184-B6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/QAI.0000000000001031","article-title":"Rilpivirine and doravirine have complementary efficacies against NNRTI-resistant HIV-1 mutants","volume":"72","author":"Smith","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023080202261538200_dkad184-B7","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/AAC.02403-13","article-title":"In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor","volume":"58","author":"Lai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202261538200_dkad184-B8","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1128\/AAC.01192-10","article-title":"Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes","volume":"55","author":"Asahchop","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202261538200_dkad184-B9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/QAD.0b013e32835d9f6d","article-title":"Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline","volume":"27","author":"Asahchop","year":"2013","journal-title":"AIDS"},{"key":"2023080202261538200_dkad184-B10","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1128\/AAC.01029-13","article-title":"Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase","volume":"57","author":"McCallum","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202261538200_dkad184-B11","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial","volume":"7","author":"Molina","year":"2020","journal-title":"Lancet HIV"},{"key":"2023080202261538200_dkad184-B12","first-page":"1336","article-title":"Once-daily doravirine for initial treatment of adults living with human immunodeficiency virus-1: an integrated safety analysis","volume":"70","author":"Thompson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023080202261538200_dkad184-B13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/cid\/ciz424","article-title":"Once-daily doravirine in human immunodeficiency virus type 1-infected, antiretroviral-naive adults: an integrated efficacy analysis","volume":"70","author":"Orkin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023080202261538200_dkad184-B14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial","volume":"68","author":"Orkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023080202261538200_dkad184-B15","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023080202261538200_dkad184-B16","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/10600280211073321","article-title":"Weight changes with integrase strand transfer inhibitor therapy in the management of HIV infection: a systematic review","volume":"56","author":"Hester","year":"2022","journal-title":"Ann Pharmacother"},{"key":"2023080202261538200_dkad184-B17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/QAD.0000000000002725","article-title":"Changes in weight and BMI with first-line doravirine-based therapy","volume":"35","author":"Orkin","year":"2021","journal-title":"AIDS"},{"key":"2023080202261538200_dkad184-B18","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/cid\/ciab444","article-title":"Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials","volume":"73","author":"Erlandson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023080202261538200_dkad184-B19","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/hiv.13268","article-title":"Major revision version 11.0 of the European AIDS Clinical Society guidelines 2021","volume":"23","author":"Ryom","year":"2022","journal-title":"HIV Med"},{"key":"2023080202261538200_dkad184-B20","first-page":"G7","author":"Department of Health and Human Services (DHHS)","year":"2022"},{"key":"2023080202261538200_dkad184-B21","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1093\/jac\/dkab126","article-title":"Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir","volume":"76","author":"Brenner","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023080202261538200_dkad184-B22","doi-asserted-by":"crossref","first-page":"e0222321","DOI":"10.1128\/aac.02223-21","article-title":"Doravirine and islatravir have complementary resistance profiles and create a combination with a high barrier to resistance","volume":"66","author":"Lai","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202261538200_dkad184-B23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/jac\/dkaa401","article-title":"In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations","volume":"76","author":"Saladini","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023080202261538200_dkad184-B24","doi-asserted-by":"crossref","first-page":"106737","DOI":"10.1016\/j.ijantimicag.2023.106737","article-title":"Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO registry","volume":"61","author":"Saladini","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2023080202261538200_dkad184-B25","doi-asserted-by":"crossref","first-page":"e01216-21","DOI":"10.1128\/AAC.01216-21","article-title":"Impact of HIV-1 resistance-associated mutations on susceptibility to doravirine: analysis of real-world clinical isolates","volume":"65","author":"Asante-Appiah","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202261538200_dkad184-B26","first-page":"979","article-title":"Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1","volume":"10","author":"Turner","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"2023080202261538200_dkad184-B27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/978-1-59745-170-3_29","article-title":"Isolation of drug-resistant mutant HIV variants using tissue culture drug selection","volume":"485","author":"Oliveira","year":"2009","journal-title":"Methods Mol Biol"},{"key":"2023080202261538200_dkad184-B28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12977-018-0440-3","article-title":"Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir","volume":"15","author":"Oliveira","year":"2018","journal-title":"Retrovirology"},{"key":"2023080202261538200_dkad184-B29","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1093\/jac\/dkx280","article-title":"M184i\/V substitutions and E138K\/M184I\/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA","volume":"72","author":"Oliveira","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023080202261538200_dkad184-B30","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1128\/AAC.46.7.2087-2094.2002","article-title":"Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT","volume":"46","author":"Loemba","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202261538200_dkad184-B31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1086\/315254","article-title":"Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States","volume":"181","author":"Sullivan","year":"2000","journal-title":"J Infect Dis"},{"key":"2023080202261538200_dkad184-B32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0042-6822(77)90389-0","article-title":"A very sensitive biochemical assay for detecting and quantitating avian oncornaviruses","volume":"80","author":"Tereba","year":"1977","journal-title":"Virology"},{"key":"2023080202261538200_dkad184-B33","doi-asserted-by":"crossref","first-page":"e25706","DOI":"10.1002\/jia2.25706","article-title":"Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa","volume":"24","author":"Steegen","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2023080202261538200_dkad184-B34","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/jac\/dkz553","article-title":"Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy","volume":"75","author":"Soulie","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023080202261538200_dkad184-B35","doi-asserted-by":"crossref","first-page":"6836","DOI":"10.1128\/JVI.76.13.6836-6840.2002","article-title":"A mutation in the 3\u2032 region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance","volume":"76","author":"Harrigan","year":"2002","journal-title":"J Virol"},{"key":"2023080202261538200_dkad184-B36","first-page":"31","article-title":"Rationale for maintenance of the M184V resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients","volume":"27","author":"Turner","year":"2004","journal-title":"New Microbiol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/8\/1921\/50967426\/dkad184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/8\/1921\/50967426\/dkad184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T22:27:59Z","timestamp":1690928879000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/8\/1921\/7193939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,6,12]]},"published-print":{"date-parts":[[2023,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad184","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,6,12]]}}}